Social Media Posts About Cancer: Five Timepoints
6. mai 2026 oppdatert av: UNC Lineberger Comprehensive Cancer Center
The main purpose of this trial was to evaluate the impact of user interface designs on intervening with cancer misinformation on social media.
The investigators conducted a randomized clinical trial with a sample of 294 US adults (ages 18-65) who previously had a cancer diagnosis or were a cancer caregiver.
This registration record only covers the 5 timepoint trial under the same IRB number.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This 5 timepoint trial aimed to determine whether user interface designs encouraged intervening and reduced sharing of cancer misinformation on social media. The investigators enrolled 294 adults, ages 18-65, who had received a cancer diagnosis or were a cancer caregiver. Participants completed 5 online surveys, space approximately 2 business days apart. In the first survey, participant were randomized to 1 of 3 trial arms, described below. During each online survey, participants interacted with a simulated social media platform, branded as Invibe. Participants had passive exposure to stimuli cancer misinformation posts and cancer support posts in social media feeds. Participants also had forced exposure to stimuli posts in the online survey after interacting with Invibe. The investigators recorded social media behavior on Invibe and assessed self-reported measures in the online survey.
This study was preregister on AsPredicted.com on March 24, 2025, prior to data collection and data analysis (https://aspredicted.org/te3su2.pdf).
Studietype
Intervensjonell
Registrering (Faktiske)
294
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- University of North Carolina at Chapel Hill
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Are ages 18-65
- Received a cancer diagnosis or have been a cancer caregiver
- Used social media
- Were willing to complete all five study timepoints
- Resided in the United States
Exclusion Criteria:
- Were unable to scroll to see posts on Invibe in the screener survey
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Social cue prompts and policy
Participants are exposed to the social cue prompts and policy intervention with cancer misinformation posts.
|
Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful by [47 or 48] people on Invibe.
If you want to report, click the flag below."
The social media launch screen had an overlaid policy for removing flagged posts: "We are committed to working with you and others on Invibe to reduce false and potentially harmful information.
When a post is flagged by 50 people, we remove it until we verify the information.
Please help us make the Invibe experience a good one for all."
|
|
Eksperimentell: Standard prompts
Participants are exposed to the standard prompts intervention with cancer misinformation posts.
|
Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful.
If you want to report, click the flag below."
|
|
Ingen inngripen: Control
Participants do not see prompts on cancer misinformation posts.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Flagging
Tidsramme: Up to 2 weeks
|
Measured with intervening behavior, defined as the flag icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to flag
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to flag this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Disliking
Tidsramme: Up to 2 weeks
|
Measured with intervening behavior, defined as the thumbs down icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Liking
Tidsramme: Up to 2 weeks
|
Measured with intervening behavior, defined as the heart icon selected.
Response options were no (coded as 0) or yes (coded as 1).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to dislike
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to dislike (thumbs down) this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to like
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to like (heart) this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to comment
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How willing are you to comment on this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Willingness to share
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "How likely are you to share or tell someone about this post?"
Responses ranged from "not at all" (coded as 1) to "extremely" (5).
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Comment valence
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "What type of comment would you write on this post?"
Response options were "comment to agree" (share), "comment to disagree" (intervene), "other," or "I would not comment."
Assessed 15 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at each timepoint approximately 2 business days apart, starting on the day of enrollment.
|
Up to 2 weeks
|
|
Sharing recipient
Tidsramme: Up to 2 weeks
|
Measured with 1 self-report survey item: "Who would you share about this post with?" Response options were "someone with cancer," "someone who is a cancer caregiver," "health-care provider," "other," or "no one."
Assessed 6 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at first timepoint and last timepoint approximately 2 weeks apart.
|
Up to 2 weeks
|
|
Sharing channel
Tidsramme: Up to 2 weeks
|
Measured with 1 self-report survey item: "How would you share about this post?"
Response options were "private message on social media," "text message," "in person," "repost on your social media," "other," and "none of these ways."
Assessed 6 times.
Assessed for 2 cancer misinformation posts and 1 cancer support post at timepoint 1 and timepoint 5 approximately 2 weeks apart.
|
Up to 2 weeks
|
|
Past week intervening behavior
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item: "In the last 7 days, did you take action against false and potentially harmful cancer posts from social media?
Select all that apply."
Response options included muted accounts, flagged posts, disliked posts, commented to correct posts, chatted with others to disagree with posts information, encouraged someone to flag or report a posts, other or did not do anything.
Assessed 1 time.
Assessed at timepoint 4 approximately a week after the day of enrollment
|
Up to 2 weeks
|
|
Past week intervening platform
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item per reported interpersonal intervening behavior: "Who did you [intervening behavior]?
Select all that apply."
Response options were "someone with cancer," "someone who is a cancer caregiver," "health-care provider," "other," or "no one."
Assessed up to 2 times.
Assessed at timepoint 4 approximately a week after the day of enrollment.
|
Up to 2 weeks
|
|
Past week intervening topic
Tidsramme: Up to 2 weeks
|
Measured with 1 self-reported survey item per reported intervening behavior: "What was the [source for intervening] about?
Select all that apply."
Response options were "to adopt a new mindset," "diet and nutrition advice," "physical activity advice," "advice to stop clinical care," "to seek treatment outside the US," or "other."
Assessed up to 6 times.
Assessed at timepoint 4 approximately a week after the day of enrollment.
|
Up to 2 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Allison J Lazard, PhD, UNC Lineberger Comprehensive Cancer Center
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
31. mars 2025
Primær fullføring (Faktiske)
12. mai 2025
Studiet fullført (Faktiske)
12. mai 2025
Datoer for studieregistrering
Først innsendt
6. mai 2026
Først innsendt som oppfylte QC-kriteriene
6. mai 2026
Først lagt ut (Faktiske)
15. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
6. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 25-0269-5TP
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Researcher may request de-identified data from participants 1 year after publication.
IPD-deling Støtteinformasjonstype
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .